title: Drug metabolism and pancreatic cancer.
abstract: Pancreatic cancer remains a fatal disease in the majority of patients. The era of personalized medicine is upon us: customizing therapy according to each patient's individual cancer. Potentially, therapy can be targeted at individuals who would most likely have a favorable response, making it more efficacious and cost effective. This is particularly relevant for pancreatic cancer, which currently portends a very poor prognosis. However, there is much to be done in this field, and more studies are needed to bring this concept to reality.
authors.affiliation: Division of Hematology/Oncology and Experimental Therapeutics, Tufts Medical Center, Boston, MA (John Paul E. Flores, Muhammad Wasif Saif).
authors.forename: John Paul E
authors.initials: JP
authors.lastname: Flores
authors.affiliation: Department of Molecular Pharmacology and Experimental Therapeutics, Mayo Clinic, Rochester, MN (Robert B. Diasio).
authors.forename: Robert B
authors.initials: RB
authors.lastname: Diasio
authors.affiliation: Division of Hematology/Oncology and Experimental Therapeutics, Tufts Medical Center, Boston, MA (John Paul E. Flores, Muhammad Wasif Saif).
authors.forename: Muhammad Wasif
authors.initials: MW
authors.lastname: Saif
keywords: Chemotherapy; genomic profile; genomics; molecular pancreatic pathogenesis; pancreatic cancer pharmacogenomics; pancreatic exocrine cancer; targeted therapy